대한예방한의학회지 (Journal of Society of Preventive Korean Medicine)

대한예방한의학회 (Society of Preventive Korean Medicine)
권호 표지
DOI QR코드

DOI QR Code

한약을 사용한 암환자 대상 임상시험에서의 항암 효능 평가변수 고찰

A Review of Anticancer Efficacy Outcome Measures in Clinical Trials of Herbal Medicine for Cancer Patients

  • 전천후 (경희대학교 한의과대학 예방의학교실 ) ;
  • 강민준 (경희대학교 대학원 한의학과 ) ;
  • 신원빈 (경희대학교 대학원 한의학과) ;
  • 송진영 (경희대학교 대학원 한의학과) ;
  • 박현석 (경희대학교 대학원 한의학과) ;
  • 양운호 (경희대학교 대학원 한의학과) ;
  • 여운석 (경희대학교 대학원 한의학과)
  • Chunhoo Cheon (Department of Preventive Medicine, College of Korean medicine, Kyung Hee University) ;
  • Min Jun Kang (Department of Korean Medicine, Graduate School, Kyung Hee University) ;
  • Wonbin Shin (Department of Korean Medicine, Graduate School, Kyung Hee University) ;
  • ;
  • Hyunsuk Park (Department of Korean Medicine, Graduate School, Kyung Hee University) ;
  • Unho Yang (Department of Korean Medicine, Graduate School, Kyung Hee University) ;
  • Unseog Yeo (Department of Korean Medicine, Graduate School, Kyung Hee University)
  • 투고 : 2024.03.22
  • 심사 : 2024.04.14
  • 발행 : 2024.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : The objective of this review is to examine the variety of evaluation parameters utilized in clinical trials that assess the anticancer efficacy of herbal medicine, focusing on the importance of including both symptomatic management and direct anticancer effectiveness. Methods : A detailed literature review was conducted across PubMed, Embase, and the Cochrane Library to identify clinical trials investigating the antitumor efficacy of herbal medicine. The search was performed on February 22, 2024. This review specifically examined the employed outcome measures, which were then categorized and analyzed to understand their relevance and application in evaluating the anticancer properties of herbal medicine. Results : From an initial search of 900 records, 15 clinical trials were selected for in-depth analysis after deduplication and screening. These studies evaluated the efficacy of herbal medicine across various cancers, including hepatocellular carcinoma, colorectal cancer, and breast cancer, using outcome measures such as survival rates, disease control rates, and quality of life improvements. The research spanned multiple countries, primarily in East Asia and the United States, reflecting a global interest in herbal medicine as a complementary approach to cancer treatment. The present study demonstrated that herbal medicine, especially when used alongside standard treatments, potentially improved clinical outcomes and patient well-being. Conclusions : The findings of this review highlight the need for a broader focus on the full range of therapeutic capabilities of herbal medicine, including its direct anticancer effects, in the management of cancer patients. Future oncology research involving herbal medicine should integrate a wide spectrum of clinical endpoints to fully ascertain its impact on cancer treatment and patient health.

키워드

과제정보

이 성과는 정부(과학기술정보통신부)의 재원으로 한국연구재단의 지원을 받아 수행된 연구임(No. 2020R1A5A2019413).

참고문헌

  1. Ferlay J, Colombet M, Soerjomataram I, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. Apr 5 2021. 
  2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. May 2021;71(3):209-249.  https://doi.org/10.3322/caac.21660
  3. Han Y, Kim HI, Park J. The Role of Natural Products in the Improvement of Cancer-Associated Cachexia. Int J Mol Sci. May 15 2023;24(10). 
  4. Yin SY, Wei WC, Jian FY, Yang NS. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med. 2013;2013:302426. 
  5. Huang G, Yin Z, Wang X, et al. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells. Phytomedicine. Aug 2023;117:154918. 
  6. Jang S, Kim KH, Sun SH, et al. Characteristics of Herbal Medicine Users and Adverse Events Experienced in South Korea: A Survey Study. Evid Based Complement Alternat Med. 2017;2017:4089019. 
  7. Luo X, Wang L, Fang S, et al. Chinese Herbal Medicine for Functional Dyspepsia With Psychological Disorders: A Systematic Review and Meta-Analysis. Front Neurosci. 2022;16:933290. 
  8. Xu GZ, Cai WM, Qin DX, Yan JH, Wu XL, Zhang HX, Hu YH, Gu XZ. Chinese herb "destagnation" series I: Combination of radiation with destagnation in the treatment of nasopharyngeal carcinoma (NPC): a prospective randomized trial on 188 cases. Int J Radiat Oncol Biol Phys. 1989 Feb;16(2):297-300.  https://doi.org/10.1016/0360-3016(89)90317-9
  9. Thompson LU, Chen JM, Li T, Strasser-Weippl K, Goss PE. Dietary flaxseed alters tumor biological markers in postmenopausal breast cancer. Clin Cancer Res. 2005 May 15;11(10):3828-35.  https://doi.org/10.1158/1078-0432.CCR-04-2326
  10. Yang YF, Chen ZX, Xu Y. [Randomized controlled study on effect of Quxie capsule on the median survival time and qualify of life in patients with advanced colorectal carcinoma]. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2008 Feb;28(2):111-4. 
  11. Zhou LY, Shan ZZ, You JL. Clinical observation on treatment of colonic cancer with combined treatment of chemotherapy and Chinese herbal medicine. Chin J Integr Med. 2009 Apr;15(2):107-11.  https://doi.org/10.1007/s11655-009-0107-y
  12. Perez AT, Arun B, Tripathy D, Tagliaferri MA, Shaw HS, Kimmick GG, Cohen I, Shtivelman E, Caygill KA, Grady D, Schactman M, Shapiro CL. A phase 1B dose escalation trial of Scutellaria barbata (BZL101) for patients with metastatic breast cancer. Breast Cancer Res Treat. 2010 Feb;120(1):111-8.  https://doi.org/10.1007/s10549-009-0678-5
  13. Saif MW, Lansigan F, Ruta S, Lamb L, Mezes M, Elligers K, Grant N, Jiang ZL, Liu SH, Cheng YC. Phase I study of the botanical formulation PHY906 with capecitabine in advanced pancreatic and other gastrointestinal malignancies. Phytomedicine. 2010 Mar;17(3-4):161-9.  https://doi.org/10.1016/j.phymed.2009.12.016
  14. Kummar S, Copur MS, Rose M, Wadler S, Stephenson J, O'Rourke M, Brenckman W, Tilton R, Liu SH, Jiang Z, Su T, Cheng YC, Chu E. A phase I study of the chinese herbal medicine PHY906 as a modulator of irinotecan-based chemotherapy in patients with advanced colorectal cancer. Clin Colorectal Cancer. 2011 Jun;10(2):85-96.  https://doi.org/10.1016/j.clcc.2011.03.003
  15. Xu ZY, Jin CJ, Zhou CC, Wang ZQ, Zhou WD, Deng HB, Zhang M, Su W, Cai XY. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol. 2011 Jul;137(7):1117-22.  https://doi.org/10.1007/s00432-011-0975-3
  16. Xu Y, Zhao AG, Li ZY, Zhao G, Cai Y, Zhu XH, Cao ND, Yang JK, Zheng J, Gu Y, Han YY, Zhu YJ, Yang JZ, Gao F, Wang Q. Survival benefit of traditional Chinese herbal medicine (a herbal formula for invigorating spleen) for patients with advanced gastric cancer. Integr Cancer Ther. 2013 Sep;12(5):414-22.  https://doi.org/10.1177/1534735412450512
  17. Chen WT, Yang TS, Chen HC, Chen HH, Chiang HC, Lin TC, Yeh CH, Ke TW, Chen JS, Hsiao KH, Kuo ML. Effectiveness of a novel herbal agent MB-6 as a potential adjunct to 5-fluoracil-based chemotherapy in colorectal cancer. Nutr Res. 2014 Jul;34(7):585-94.  https://doi.org/10.1016/j.nutres.2014.06.010
  18. Cheon C, Ko SG. A Phase I Study to Evaluate the Safety of the Herbal Medicine SH003 in Patients With Solid Cancer. Integr Cancer Ther. 2020 Jan-Dec;19:1534735420911442. 
  19. Jia R, Liu N, Cai G, Zhang Y, Xiao H, Zhou L, Ji Q, Zhao L, Zeng P, Liu H, Huo J, Yue X, Zhang Y, Wu C, Sun X, Feng Y, Liu H, Liu H, Han Z, Lai Y, Zhang Y, Han G, Gong H, Wang Y, Li Q. Effect of PRM1201 Combined With Adjuvant Chemotherapy on Preventing Recurrence and Metastasis of Stage III Colon Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Front Oncol. 2021 Mar 3;11:618793. 
  20. Yang X, Feng Y, Liu Y, Ye X, Ji X, Sun L, Gao F, Zhang Q, Li Y, Zhu B, Wang X. Fuzheng Jiedu Xiaoji formulation inhibits hepatocellular carcinoma progression in patients by targeting the AKT/CyclinD1/p21/p27 pathway. Phytomedicine. 2021 Jul;87:153575. 
  21. Changou CA, Shiah HS, Chen LT, Liu S, Luh F, Liu SH, Cheng YC, Yen Y. A Phase II Clinical Trial on the Combination Therapy of PHY906 Plus Capecitabine in Hepatocellular Carcinoma. Oncologist. 2021 Mar;26(3):e367-e373.  https://doi.org/10.1002/onco.13582
  22. Zhang T, Xu Y, Sun LY, He B, Hao J, Zhang D, Yang YF. Efficacy of Quxie Capsule in Metastatic Colorectal Cancer: Long-Term Survival Update of A Double-Blind, Randomized, Placebo Controlled Trial. Chin J Integr Med. 2022 Nov;28(11):971-974.  https://doi.org/10.1007/s11655-021-3281-1
  23. Lee JY, Kim EH, Yoon JH, Eo W, Yoon SW. Traditional Herbal Medicine, Sipjeondaebo-Tang, for Cancer-Related Fatigue: A Randomized, Placebo-Controlled, Preliminary Study. Integr Cancer Ther. 2021 Jan-Dec;20:15347354211040830. 
  24. Jo HG, Seo J, Choi S, Lee D. East Asian Herbal Medicine to Reduce Primary Pain and Adverse Events in Cancer Patients : A Systematic Review and Meta-Analysis With Association Rule Mining to Identify Core Herb Combination. Front Pharmacol. 2022 Jan 17;12:800571. 
  25. Hess LM, Brnabic A, Mason O, Lee P, Barker S. Relationship between Progression-free Survival and Overall Survival in Randomized Clinical Trials of Targeted and Biologic Agents in Oncology. J Cancer. 2019 Jun 9;10(16):3717-3727.  https://doi.org/10.7150/jca.32205
  26. Chapter 1 - Guidelines for Radiologic Reporting of Common Cancers. In: Hricak H, Husband J, Panicek DM, eds. Oncologic Imaging. Philadelphia: W.B. Saunders; 2007:2-13 
  27. Sznol M. Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype? Curr Opin Investig Drugs. 2010 Dec;11(12):1340-1.